Prophylactic rituximab administration in children with complicated nephrotic syndrome

Mika Okutsu(National Center For Child Health and Development), Kenji Ishikura(Kitasato University), Toru Kanamori(National Center For Child Health and Development), Kentaro Nishi(National Center For Child Health and Development), Shuichi Ito(Yokohama City University), Koichi Kamei(National Center For Child Health and Development), Mai Sato(Kyoto University), Masao Ogura(Hokkaido University Hospital), Mayumi Sako(National Center For Child Health and Development), Sho Ishiwa(National Center For Child Health and Development)
Pediatric Nephrology
September 30, 2020
10.1007/s00467-020-04771-5
Cited by 8

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135